Pular para o conteúdo principal

Genomic data management is in our DNA

A person working in a lab
Contents

Compartilhar esta página

linda-kallfa
Linda Kallfa
118 visualizações

Next-generation sequencing (NGS) has revolutionized genomic research by empowering scientists to sequence genomes at vastly higher speeds. In drug discovery research, NGS is now an indispensable tool for pharmaceutical firms—one that’s cheaper, faster, and produces more promising candidate medicines than conventional methods.

NGS is employed from the earliest stages of drug discovery to provide detailed genomic data that can be used in clinical applications. Those applications range from investigations into the molecular basis of drug resistance to vaccine development, to disease diagnostics.

For all its incredible potential, however, NGS brings with it a lot of tricky data management questions. That's where NetApp can help.

For datasets, size matters

NGS is helping pharmaceutical companies derive greater insights into complex clinical causes of human diseases and enhance safety through multivigilance—the monitoring and reporting of risks (specifically for patients) in new and existing drugs, biologics, and vaccines.

In doing so however, NGS generates huge and complex datasets so rapidly that it creates a bottleneck for analysis. According to the National Human Genome Research Institute, part of the National Institutes of Health, it's estimated that within the next decade, genomic research will generate between 2EB and 40EB of data.

Pharma companies therefore must vastly upscale their data handling capacity to enable genomics teams to store and transfer large data volumes quickly and easily. They also must deploy computational tools that can handle, extract, and interpret the these large troves of data and unlock the valuable information hidden—especially tools that deploy heuristic algorithms and artificial intelligence (AI).

Gartner has identified a growing need to efficiently manage and make full use of genomic data. A 2021 Gartner report states, “By 2023, 40% of the top 25 healthcare and life science companies will have a genomics technology enterprise strategy and be actively leveraging genomics data in developing new products and therapies.”

AI-driven insights: Using one code to crack another

Advanced analytics improve understanding by revealing hidden patterns in large and complex genomic datasets. By using conventional methods, those patterns would typically be far more difficult to discover—if they could be discovered at all. Even in the early stages of its deployment, NGS is transforming drug discovery by taking a deeper look into the genetic clues behind disease.

Machine learning (ML) and AI help process genomic data gathered from NGS with an extremely high degree of speed and accuracy, while still being a more cost-effective approach to the measurement of genetic variation. This can transform previously unwieldy volumes of data into tangible and valuable assets.

For researchers, too, AI and ML represent a significant time save. Algorithms that can read, group, and interpret data automatically offer a more efficient way to examine data, replacing the laborious task of manually processing and interpreting datasets. Researchers can then spend more time analyzing and drawing conclusions rather than collating data.

Good quality data and a strong data pipeline are the core ingredients for AI and ML success. To maximize effectiveness, the quality, amount, source, diversity, and reliability of the data must all be considered. NetApp® technology offers you the control needed to understand, manage and package your genomic data in an AI and ML-friendly fashion, meaning you’re able to extract valuable genomic insights.

NetApp technology key advantages

Together with our partner offerings, NetApp life sciences solutions can help speed genomic research breakthroughs and cut time to market. For example:

  • NetApp and its partner PetaGene offer multiple options for managing and seamlessly transferring your organization's genomic data across diverse cloud environments.
  • You can tier cold data to object storage, freeing your performance tiers for new sequencing projects.
  • PetaGene’s PetaSuite software shrinks large genomic files to make them more portable, giving you immediate data-flow benefits and up to 10 times higher data efficiency.
  • With NetApp technology and Parabricks from NetApp partner NVIDIA, you can deploy a fully integrated, end-to-end AI solution that's tuned for genomic workloads.
  • With all-flash storage from NetApp and NVIDIA, you can significantly boost speed and accuracy for AI-powered precision calculations.
  • NetApp GPU-accelerated genome sequencing is 50 times faster compared with CPU-only solutions, maximizing your data throughput and minimizing turnaround time.

Learn more

Help your organization keep pace with the growth of genomic data. Learn more about NetApp life sciences solutions.

linda-kallfa

Linda Kallfa

Linda lidera a prática de Ciências da vida dentro da equipe de Saúde e Ciências da vida. Ela traz sua experiência em farmacêutica e ciências da vida para conversas com clientes, conetando o valor dos produtos e serviços da NetApp à linha de negócios com foco na descoberta de medicamentos, ensaios clínicos virtuais e híbridos, análise de imagens, digital e além das iniciativas de pílula. Com 15 anos de experiência global, Linda começou sua carreira na GlaxoSmithKline R&D trabalhando como cientista de inovação em seu Centro de Excelência. Ela então gerenciou o desenvolvimento clínico de várias marcas enquanto trabalhava em parceria com equipes comerciais globais. Querendo fazer parte da transformação digital na indústria farmacêutica, Linda juntou-se à Medidata, uma empresa pioneira de pesquisa clínica e gerenciamento de dados, onde ajudou clientes em toda a EMEA a adotar a plataforma Medidata Rave. Linda então se juntou à QAD, um provedor de ERP de ponta a ponta, como executiva de desenvolvimento de negócios em sua unidade de negócios Life Sciences. Ela assessorou clientes de dispositivos médicos e farmacêuticos em soluções ERP para seus departamentos de qualidade, cadeia de suprimentos e fabricação digital. Em parceria com o marketing de soluções, Linda iniciou um programa inicial de adoção de ERP para fabricantes de células e genes. Linda é membro da Healthcare Businesswomen's Association (HBA).Ver todas as publicações de Linda Kallfa

Próximas etapas

Genomic data management is in our DNA